Skip to content
Home/Companies/Biotech/Immutrin
Immutrin

Immutrin

Biotech·UK·Active·1yr hold
Entry
2025
Hold
1yr
Status
Active

Who owns Immutrin?

Immutrin is a British Biotech company, currently owned by Cambridge Innovation Capital since 2025.

Hand-verified · updated 2026-07-08

Open JSON · CC-BY
Cambridge Innovation Capital
Investor
Cambridge Innovation Capital
CIC Fund II · 2022 · VC

Key facts

HQUK
SectorBiotech
StatusActive
Websitewww.immutrin.com

More from CIC Fund II

Other portfolio companies in the same fund.

TRIMTECH Therapeutics
TRIMTECH Therapeutics
Active
BiotechUK· 2025
Forefront RF
Forefront RF
Active
TelecomUK· 2024
Nuclera
Nuclera
Active
BiotechUK· 2024
Sortera Bio
Active
United Kingdom· 2024
Complement Therapeutics
Complement Therapeutics
Active
BiotechUK· 2023
Mosaic TX
Mosaic TX
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Immutrin?

Immutrin is currently owned by Cambridge Innovation Capital, through CIC Fund II, since 2025.

When did Cambridge Innovation Capital acquire Immutrin?

Cambridge Innovation Capital acquired Immutrin in 2025.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue